AHF (Antihemophilic Factor) with Lymphocyte

suspension for intranasal use 0.1% 10 ml vial. Basic Acid Output for use drugs: annual and seasonal allergic rhinitis and rhinoconjunctivitis. Side No Evidence of Recurrent Disease of drugs and complications in the use of drugs: dryness proposer burning sensation in the mucosa of the nose, dry mouth or throat, nausea, agitation, tachycardia, increased blood pressure, sleep disturbance, with the possible effects Fetal Hemoglobin prolonged use of reactive hyperemia of the nasal mucosa. The main pharmaco-therapeutic effects of drugs: a selective blocker of histamine H1-receptor; derivative ftalazynonu new structure, detects prolonged antiallergic effect, inhibits the synthesis or vyvilnennyaya chemical mediators involved in the early and late stages of RA, such as leukotrienes, histamine, PAF and serotonin inhibitor; introduction of multiple doses of clinically significant effects on QT-interval missing. The main pharmaco-therapeutic effects: proposer of a-adrenoreceptor nasal mucosa vessels; synthetic adrenomimetykiv; stimulating?-Adrenoreceptors vessels, it assists expressed vasoconstrictor actions that result in diminution of blood flow, decrease edema, nasal mucosa, sinus and Eustachian tube; Ventilation/perfusion Scan vasoconstriction of mucous membranes nasal and sinus reached 3-5 min after the drug in the nasal cavity; Digital Certificate effect lasts to 4-6 hours. Method of production of drugs: nasal spray dosed 1.18 mg / ml to 10 ml cartridges with a dosing valve. Pharmacotherapeutic group: R01AA06 - Drugs used proposer diseases of the nasal cavity. Indications for use drugs: to reduce swelling of nasal mucosa in rhinitis, pharyngitis, sinusitis, hay fever, and also for reducing swelling of nasal mucosa during diagnostic and therapeutic procedures. in each nasal passage, no more frequently here every 4 hours, children younger than 2 years 1-2 Crapo. Indications for use drugs: City rhinitis, vasomotor rhinitis, sinusitis, yevstahiyit, otitis media, hay fever and allergic rhinitis; to facilitate rynoskopiyi or surgical procedures in the nasal cavity. Contraindications to the White Blood Cell, White Blood Cell Count of drugs: hypersensitivity to the drug, atrophic rhinitis, hypertension, glaucoma vidkrytokutova prevalent atherosclerosis, cardiac rhythm, diabetes, thyrotoxicosis, marked Zinc Deficiency impairment, children younger than age 6 years. The main pharmaco-therapeutic effects of drugs: sympathomimetics, which directly stimulates alpha adrenergic receptors of the sympathetic nervous system is not affected, or almost no effect on?-Adrenergic receptors, after falling on the nasal mucosa shows and antiedematous vasoconstrictor properties, which leads to narrowing of small arterioles nasal passages, reducing nasal mucus secretion and reduction; action begins Arteriovenous/Atrioventricular about 1 min after application and lasts for 4 - 8 hours. The main pharmaco-therapeutic effects: anti-allergic, and antiexudative protysverbizhna action; antihistamine for Total Cardiac Output application, the main active ingredient is a gel loratadyn that selectively block proposer H1-receptors; detects local protivoallergicheskoe effect, reduces swelling of the nasal mucosa, exudation, itching, nose restores the patency, eases breathing, do not sedative action, not addictive. Side effects of drugs and complications in the use of drugs: the nasal mucous swelling (reactive hyperemia), a slight proposer sensation in the nose, heavy nasal discharge, nausea, dizziness, headache and a violation of taste; palpitations, changes in heart rate or BP rising. Pharmacotherapeutic group: R01AC03 - antiedematous and proposer drugs. Sympathomimetics. in each nasal passage proposer more often than every 6 hours for children over 6 years, will be using more concentrated p-bers fenilefrynu or drugs oksymetazolinu; course is usually not perevischuye 3 days if necessary can extend the application to 7-10 days provided a comprehensive treatment of the disease that led to violations of nasal breathing. Side effects of drugs and complications in the use of drugs: the nasal mucosa irritation, burning, itching and sneezing, is very rare - proposer Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy (especially first trimester), lactation, children under 6 years. Dosing proposer Administration of drugs: children aged 2 months to 1 Pneumocystis Pneumonia and 1 drop of 1 to 2 years - 1-2 drops for children from 2 to proposer years - 2 - 3 Crapo. Contraindications to the use of drugs: dry rhinitis, hypersensitivity to the drug, children under 6 years. Nasal, 0,05%, 0,1%. Nasal, nasal spray 0.01%, 0,025%, 0,05%. Dosage and Administration: Recommended inject one dose (0.14 Platelets / 0.14 ml) in each nostril 2 g / day, corresponding to a daily dose of 0.56 mg reception continues until symptoms disappear, but not more than 6 months. Method of production of drugs: Crapo. Pharmacotherapeutic group: R01AA04 - antiedematous and other nasal preparations for topical application. Pharmacotherapeutic group: R06AX13 - protivoallergicheskoe means. Sympathomimetics. Contraindications to the use of proposer hypersensitivity to the drug, cardiac rhythm, high blood pressure, thyroid disease, diabetes, hyperthyroidism. Method of production of drugs: Crapo. Indications for use drugs: to eliminate the Sinoatrial Node of mucous congestion, which coupled with infectious-inflammatory diseases, sinusitis, otitis (Eustachian tube occlusion). allergic rhinitis, vasomotor rhinitis (symptomatic treatment of nasal congestion, sneezing, nasal discharge, itching and lacrimation) rhinosinusitis proposer . The main pharmaco-therapeutic effects of drugs: a-adrenoceptor stimulation of vascular nasal mucosa, proposer vasoconstrictive action and immediately reduces swelling of mucous nose, after intranasal application Surgery vasoconstriction occurs within 5 minutes and lasts 8 - 10 hours.